CN Patent

CN101137383B — 增强型比马前列素眼用溶液

Assigned to Allergan Inc · Expires 2011-06-15 · 15y expired

What this patent protects

本文公开了一种组合物，包括以重量百分比计0.005％至0.02％的比马前列素和100ppm至250ppm的苯扎氯胺，其中所述组合物是按配方配制的用于眼用给药的水成液。此外本文也公开了一种可用于治疗青光眼或相关的高眼压症的方法。

USPTO Abstract

本文公开了一种组合物，包括以重量百分比计0.005％至0.02％的比马前列素和100ppm至250ppm的苯扎氯胺，其中所述组合物是按配方配制的用于眼用给药的水成液。此外本文也公开了一种可用于治疗青光眼或相关的高眼压症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN101137383B
Jurisdiction
CN
Classification
—
Expires
2011-06-15
Drug substance claim
No
Drug product claim
No
Assignee
Allergan Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.